Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors

Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors

Background Metabolomics has the characteristics of terminal effects and reflects the physiological state of biological diseases more directly. Several current biomarkers of multiple omics were revealed to be associated with immune-related adverse events (irAEs) occurrence. However, there is a lack o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juan Chen, Jun-yan Liu, Fan Yang, Ting Zou, Zhan Wang, Jia-Si Liu, Lei She, Xiang-Ping Li, Zhaoqian Liu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/7/e009399.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
by: Ping Luo, et al.
Published: (2025-12-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese center
by: Wenwen Gong, et al.
Published: (2025-07-01)

Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-03-01)

Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience
by: Inès Cherradi, et al.
Published: (2025-01-01)

Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study
by: Pengfei Zhao, et al.
Published: (2025-04-01)

Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
by: Mengyuan Liu, et al.
Published: (2025-05-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
by: Yanling Wang, et al.
Published: (2025-04-01)

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
by: Seok Jun Park, et al.
Published: (2025-01-01)

Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy
by: Bo-Ya Li, et al.
Published: (2025-05-01)

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors
by: Qiuying Qin, et al.
Published: (2025-06-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024-07-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
by: Yanxin Chen, et al.
Published: (2025-01-01)

PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01)

Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors
by: Rui Huang, et al.
Published: (2022-01-01)

Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
by: Chen-xing Jin, et al.
Published: (2025-04-01)

Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy
by: Yunyi Du, et al.
Published: (2024-12-01)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
by: Zhenzhen Fan, et al.
Published: (2020-05-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Advances in PD-1 and PD-L1 inhibitors targeted therapies for NSCLC: Mechanisms, Biomarkers, Combination Therapies
by: Xiang Zhiyuan
Published: (2025-01-01)

Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review
by: Lijing Zeng, et al.
Published: (2025-07-01)

Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD‐1/PD‐L1 Blockade in Patients With Non‐Small Cell Lung Cancer
by: Kiyoshi Takagaki, et al.
Published: (2025-05-01)

Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: a retrospective study
by: Wentong Liu, et al.
Published: (2025-08-01)

The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors
by: A. D. Koltakova, et al.
Published: (2022-10-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)